105245-87-2 Usage
General Description
1-(2,5-Dioxo-2,5-dihydro-1H-imidazol-4-yl)urea, also known as thienopyrimidinone, is an organic compound belonging to the class of ureas. It is a synthetic compound with a molecular formula of C5H6N4O3 and a molecular weight of 166.12 g/mol. This chemical is widely used in the pharmaceutical industry as a building block for the synthesis of various pharmaceutical compounds, due to its ability to incorporate into drug molecules and modify their biological properties. Additionally, research has shown that 1-(2,5-Dioxo-2,5-dihydro-1H-imidazol-4-yl)urea exhibits potential antitumor and anti-inflammatory activities, making it a promising candidate for further drug development. Despite its potential benefits, the chemical's safety and potential hazards should be carefully evaluated before its use in various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 105245-87-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,5,2,4 and 5 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 105245-87:
(8*1)+(7*0)+(6*5)+(5*2)+(4*4)+(3*5)+(2*8)+(1*7)=102
102 % 10 = 2
So 105245-87-2 is a valid CAS Registry Number.
105245-87-2Relevant articles and documents
THE MECHANISM FOR THE CONVERSION OF URIC ACID INTO ALLANTOIN AND DEHYDRO-ALLANTOIN. A NEW LOOK AT AN OLD PROBLEM
Poje, M.,Sokolic-Maravic, Lea
, p. 747 - 752 (2007/10/02)
The reaction of uric acids 1 with iodine in alkaline solution yields, on acidification, new dehydroallantoins 11, or normal oxidation products, allantoins 13, depending on whether an excess or a stoichiometric amount of oxidant was used.The structure and regiochemistry of dehydro-allantoins 11 was established by chemical, spectroscopic, and 14C-labelling methods.These experimental results, in combination with other data, generate a new mechanistic scheme for the uricolytic pathway to allantoin, ruling out the intervention of a symmetrical transition state prior to the decarboxylation step.
